Introduction
Of the 192 000 North Americans who develop breast cancer every year, approximately 15% will develop liver metastases. 1 The overall prognosis for these patients is poor, with treatment options usually limited to chemotherapy or hormonal treatments. To further complicate matters, metastatic breast tumours rarely maintain oestrogen and progesterone receptor positivity, limiting the effectiveness of hormonal treatments. 2 Even in the best series, including optimized medical treatment, the median survival is low. [3] [4] [5] [6] [7] [8] The one subset of this population that may have additional treatment options are the 4-5% of patients with breast cancer metastases limited to the liver. 9 These patients have the potential to be managed surgically, with either hepatic resection or radiofrequency ablation (RFA).
Several case series have reported an improvement in survival for patients who underwent hepatic resection for liver-only metastatic disease, with 5-year survival rates ranging from 9% to 61%. 10, 11 The majority of patients treated with resection had limited disease, usually less than four tumours distributed advantageously to allow for complete tumour resection. Many breast cancer patients, however, are poor candidates for a major surgical intervention. RFA is a minimally invasive procedure which offers a low-risk alternative to resection for the definitive treatment of liver tumours. When properly applied, RFA results in the complete focal destruction of the target tumour and a margin of normal tissue. RFA can be performed either percutaneously or under surgical guidance. Percutaneous RFA is less invasive than surgical RFA; however, surgery has the advantages of allowing for more accurate staging of the disease, more aggressive ablation without the risk of injury to surronding structures, and if performed laparoscopically, adds only minimal morbidity. 12 While the use of RFA for the treatment of breast cancer liver metastases has been anecdotally described, its role remains poorly defined. [12] [13] [14] [15] [16] [17] [18] [19] The present study reviews a single institution's experience with the surgical staging and selective treatment of breast cancer metastatic to the liver using hepatic resection and laparoscopic RFA. Outcomes of patients who underwent surgical management of BCLM with an intention to treat are compared to a review of the existing published literature.
Methods
Between December 1998 and August 2006, 17 patients diagnosed with breast cancer with metastases limited to the liver were considered for surgical management with either laparosopic RFA or hepatic resection. All procedures were performed by a single surgeon, and data were obtained retrospectively from an insitutional review board (IRB)-approved hospital database.
Patient selection
Pre-operative work-up included a history and physical, complete blood count, complete metabolic panel and tumour marker studies. All patients underwent a three-phase computed tomography (CT) or magnetic resonance image (MRI) scan to assess tumour burden in the liver before sugery was considered.
Patients were typically considered for surgical management if they had limited co-morbidities, four or fewer liver tumours and no (or limited and stable) extrahepatic disease on pre-operative imaging. Based largely on our experience with colorectal liver metastases, patients were preferentially considered for laparoscopic RFA if they had significant co-morbidities, four or fewer liver tumours all <4 cm in size, tumours located more than 1 cm from the central biliary structures and no (or limited and stable) extrahepatic disease on pre-operative imaging. Hormone receptor and HER2 status was not a determining factor for patient selection. Pre-operative chemotherapy was used at the discretion of the referring oncologist or surgeon. All patients were presented and discussed at a multidisciplinary tumour board.
All patients were taken to the operating room for a planned staging laparoscopy and intra-operative ultrasound (IOUS). Patients then underwent treatment with either laproscopic radiofrequency ablation or hepatic resection at the discretion of the surgeon. If patients did not meet criteria for either laparoscopic RFA or hepatic resection, the procedure was aborted. These patients were followed in clinic 2 weeks post-operatively to record acute surgical outcomes, and were then referred back to their oncologist for consideration of systemic chemotherapy.
Surgical technique: hepatic resection
Hepatic resection was performed using standard techniques for either anatomic or non-anatomic resection. After the completion of laparoscopic staging, a determination was made regarding the best approach, open or laparoscopic. The ligamentous attachments of the liver were divided for complete mobilization. Extraparenchymal division of the portal pedicle and hepatic venous outflow was performed and the parenchyma was divided with a combination of ultrasonic coagulation, electrocautery or surgical stapling.
Surgical technique: laparoscopic RFA Laparoscopic RFA is a minimally invasive technique performed under general anaesthesia, which uses a high-frequency alternating current to produce heat, resulting in local tumour destruction. All of the patients underwent a diagnostic staging laparoscopy including IOUS before treatment with RFA. In the absence of extrahepatic disease, the RFA probe is placed into the tumour under ultrasound guidance and the probe is deployed into the tumour bed. The tumour tissue is heated to at least 60°C ensuring complete cell death is achieved. A double ablation of each tumour is routinely performed by retracting the RFA probe tines after the first ablation, turning the shaft of the device 30°and redeploying the tines into the tumour and repeating the ablation. The treatment goal is to destroy the tumour and a 1-cm margin of normal liver tissue circumferentially. If the tumour and required margins are larger than the maximal diameter of the ablation probe, a series of overlapping ablations are performed. All laparoscopic RFA procedures were performed using either the RITA XL or RITA XLi ablation device (RITA Medical Systems Inc., Mountain View, CA, USA).
Tumour response and follow-up Surgical follow-up for all patients included a post-operative visit with a CT scan at 2 weeks (new baseline), subsequent follow-up visits and repeat imaging studies every 3 months for 2 years and then every 6 months until 5 years. Complete tumour response was defined as the absence of arterial enhancement within or at the periphery of all treated tumours on post-operative imaging. Adjuvant systemic chemotherapy was offered at the discretion of the medical oncologist.
Data collection and analysis
Patient demographics, procedural data, complication data and recurrence data were obtained from an IRB-approved hospital database. All data were analysed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results

Demographics
Seventeen patients diagnosed with breast cancer metastatic to the liver were considered for surgical management. The median patient age was 59.4 years (range, 41.1-67.1), and all patients were female. All patients were sent for surgical evaluation because of either newly identified liver metastases or progression of existing metastases on chemotherapy. Fourteen patients had metastatic disease confined to the liver, two patients had concurrent metastases to the bone and one patient had a concurrent metastasis to the lung. Extrahepatic disease had been stable on preoperative imaging for more than 6 months before surgical treatment. All patients had undergone a resection of their primary breast cancer (nine lumpectomy and eight mastectomy) before the diagnosis of liver metastases. Six patients had positive axillary nodes at the time of the resection for primary cancer, eight patients had primary tumours that were oestrogen-receptor positive and two patients had primary tumours that were progesterone-receptor positive. HER2 status was available for only nine patients, three of which were HER2 positive. Sixteen patients had undergone prior treatment with systemic chemotherapy and radiation for their primary breast cancer. The median number of months between diagnosis of primary breast cancer and subsequent liver metastases was 44.6 months (range, 1.0-231.2). The median number of liver metastases identified on pre-operative three-phase CT-scan or MRI was one tumour (range, 1-4) and the median tumour size was 3.3 cm (range, 1.3-5.0). Pre-operative patient demographics and prior treatment data are summarized in Table 1 . Three patients had an American Association of Anesthesiologists (ASA) classification of 2, 10 patients had an ASA of 3 and four patients had an ASA of 4.
Procedure Eight patients were deemed inelligible to undergo treatment upon exploratory laparoscopy and IOUS (unresectable or un-ablatable disease), and the procedures were aborted. Seven patients underwent complete ablation of all metastatic lesions with laparoscopic RFA, and two patients underwent hepatic resection.
Of the patients who underwent treatment with laparoscopic RFA, the median number of tumours ablated was 1 (range, 1-6), and the median tumour size was 3.0 cm (range, 1.6-5.9). The median procedure time for staging laparoscopy, IOUS and RFA was 157 min (range, 105-245), and median blood loss was 50 ml (range, 0.0-150.0). Post-operatively, the median length of stay was 2 days (range, 1-9 days).
Two patients underwent hepatic resection (one laparoscopic left lateral hepatic segmentectomy and one open formal left hepatectomy with caduate lobe resection). Both patients presented with a single hepatic metastasis less than 5 cm in largest diameter. The median procedure time for staging laparoscopy, IOUS and hepatic resection was 325 min (range, 356-413), and blood loss was less than 750 ml in both patients. The first patient was discharged on post-operative day 2, and the second patient was discharged on post-operative day 3.
Eight patients were found to have extensive disease within the liver on staging laparoscopy and IOUS that was not amenable to either laparoscopic RFA or hepatic resection. Five of these patients were found to have more than 10 tumours on laparoscopy, dis- tributed throughout both the left and right hepatic lobes. One patient was a poor surgical candidate, and was found to have a large tumour adjacent to the central biliary structures that was deemed unsafe for ablation. Another patient presented with six tumours, one of which was greater than 4 cm in diameter on intra-operative ultrasound. The final patient was found to have portal lymph nodes positive for poorly differentiated adnocarcinoma on intra-operative biopsy. One major complication was reported in a patient who underwent laparoscopic RFA. The patient suffered a pulmonary embolus on post-operative day 5 which required anticoagulation, and was discharged home on post-operative day 9. No complications were reported in patients who underwent hepatic resection, or staging laparoscopy alone.
Procedural and outcomes data for all patients are summarized in Table 2 .
Survival and disease recurrence
The median length of follow-up for patients who underwent surgical treatment with either laparoscopic RFA or hepatic resection was 40.0 months, and the median disease-free survival was 32.2 months.
Of the patients who underwent surgical treatment with laparoscopic RFA, five patients developed disease recurrence within the liver. None of these recurrences, however, were located at an RFA site. One patient also developed distant metastases to the lymph nodes and bone. The median time to disease progression within the liver after laparoscopic RFA was 17.7 months. All patients with disease recurrence went on to have systemic chemotherapy for further management of disease. Of the patients who underwent hepatic resection, one patient presented with disease recurrence within the liver at 8.0 months, and died at 9.9 months postoperatively. This patient chose to undergo palliative chemotherapy after the diagnosis of disease recurrence. The second patient remained disease-free, and died at 65 months of unrelated causes.
Of the eight patients who were not amenable to either laparoscopic RFA or hepatic resection, the median length of follow-up was 21.8 months. All patients were referred to an oncologist for further management of their disease, and subsequent treatment with systemic chemotherapy was offered at the discretion of the oncologist. Five patients underwent systemic chemotherapy, and three patients declined further treatment.
Discussion
There are limited data in the published literature evaluating the use of local surgical therapies for the treatment of BCLM. Hepatic resection has traditionally been considered the 'gold standard' for management of any primary and metastatic disease within the liver, however, it is estimated that only 1-3% of these patients are candidates for hepatic resection. 20, 21 Hepatic resection carries a moderate risk of peri-operative morbidity, and to be eligible patients must have limited co-morbidities and a tumor distribution within the liver which allows for an adequate functional hepatic remnant. Patients diagnosed with BCLM generally have such a poor prognosis that treatment options are often palliative, and the risk of major post-operative morbidity associated with hepatic resection may not be warranted.
Minimally invasive procedures such as RFA have proven valuable in selected patients with isolated hepatic metastases and can be utilized in patients who are not candidates for hepatic resection. 12 RFA is associated with a low rate of post-operative morbidity and can be performed percutaneously, laparoscopically or during open surgery. The majority of the published studies describing RFA for BCLM utilize the percutaneous approach. During percutaneous RFA, the ablation probe is placed directly into the tumour under CT guidance. Percutanous RFA is limited in that peritoneal as well as new hepatic metastases cannot be directly visualized before ablation. Smaller lesions or peritoneal metastases which may not enhance on pre-operative imaging can often only be identified intra-operatively under direct visualization. A laparoscopic approach allows for more accurate staging with direct visualization and typically requires only two 10-mm incisions. In the present study, 8 out of 17 patients who were felt to have metastatic disease confined to the liver, which was potentially resectable, were discovered to have widely metastatic or unresectable lesions. This 47% incidence of untreatable disease identified during SL/IOUS is higher than that reported in most series for BCLM. Adam et al. found that in 108 patients taken to the operating room for surgical management of BCLM, 34% of patients had more disease than anticipated by pre-operative imaging, although only 21% were ultimately considered untreatable. 22 However, the present study included patients who were not candidates for resection, but were candidates for RFA, accounting for 2 of the 8 aborted procedures. Had these patients been removed from the analysis, the aborted procedure rate would be 40%. Still, 6 of 17 patients in our series had disease not manageable by surgical intervention, leading to the conclusion that SL/IOUS is necessary before surgical management of BCLM.
Within the current study there were no RFA treatment site failures. Five patients who underwent RFA developed disease progression elsewhere in the liver. The median time to disease progression in these patients was 17.7 months. The rate of regional progression after treatment with RFA reported in this series is similar to other studies reporting outcomes of BCLM in the published literature, which range from 50-58%. 15, 18 One of the two patients who underwent treatment with hepatic resection, presented with regional recurrence 8.0 months post-operatively. This patient chose to undergo pallative chemotherapy, and died shortly after. The second patient remained disease-free, and died at 65 months of unrelated causes.
In the present study, the median survival for patients treated with either hepatic resection or laparoscopic RFA was 40.0 months. These data are similar to other non-randomized retrospective studies published in the literature (Table 3) . It has been reported that the median survival for patients with BCLM who undergo treatment with either hepatic resection or RFA ranges from 19-63 months and 9-60 months, respectively. 12, 23 This suggests that median survival for patients who undergo laparoscopic RFA or hepatic resection is longer than that of patients treated with chemotherapy alone (range, 4.5-27.1 months), and may provide some benefit to a select group of patients with BCLM by delaying disease progression and prolonging survival.
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Conclusion
The present study clearly demonstrates the importance of SL/IOUS before locoregional intervention for patients with BCLM. It also suggests that laparoscopic RFA and hepatic resection are safe surgical treatments in patients with BCLM. Further, the use of RFA led to no treatment site failures and low morbidity, suggesting that it may be an acceptable alternative to surgical resection in selected patients.
The number of patients in this series is small and the follow-up is relatively short, making it difficult to draw a meaningful conclusion regarding the appropriateness of aggressive surgical management in patients with BCLM.
The authors' current practice, guided by this series review and the existing literature, is to laparoscopically stage all patients being considered for surgical mangement of BCLM. Resection and/or RFA are selectively pursued in patients with four or fewer lesions. Lesions less than 3 cm in diameter may be considered for RFA.
